Physician profile
Caroline P Cella
NPI 1679522098
$2,598.16
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $507 · 2021: $354 · 2022: $849.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.05 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $311.18 | 2019-2022 | |
| Abbvie INC. | $234.71 | 2021-2022 | |
| Pfizer INC. | $196.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $191.18 | 2019-2022 | |
| Lilly USA, LLC | $190.19 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $132.33 | 2022 | |
| Amgen INC. | $120.48 | 2019-2022 | |
| Abbott Laboratories | $114.77 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.52 | 2020-2021 | |
| Astellas Pharma US INC | $90.67 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.58 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $44.32 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $39.51 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $31.12 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.70 | 2021 | |
| Esperion Therapeutics, INC. | $25.71 | 2021-2022 | |
| Eisai INC. | $21.61 | 2019 | |
| Boston Scientific Corporation | $18.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.79 | 2019 | |
| Dynavax Technologies Corporation | $18.53 | 2019 | |
| Biogen, INC. | $16.44 | 2021 | |
| Concordia Pharmaceuticals INC. | $14.58 | 2019 | |
| Adlon Therapeutics L.P. | $12.97 | 2021 | |
| Allergan, INC. | $12.89 | 2020 | |
| Sanofi Pasteur INC. | $11.50 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.44 | 2019 | |
| Amarin Pharma, INC. | $11.29 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Cella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.